Jacki Degolyer
Primary Care · Denver, CONPI 1356912497
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $809 and has fallen 82.2% since, to $144 in 2025.
Across 80 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$374
- Viiv Healthcare Company$200
- Amgen$168
- AstraZeneca$148
- AbbVie$107
- Pfizer$102
- plus $639 from 19 others
What the payments were for
- Food & beverage$1,738100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $374 |
| Viiv Healthcare Company | 12 | $200 |
| Amgen | 8 | $168 |
| AstraZeneca(2 entities) | 3 | $148 |
| AbbVie | 5 | $107 |
| Pfizer | 6 | $102 |
| Astellas Pharma US Inc | 4 | $88 |
| Bayer | 4 | $80 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| Gilead | 2 | $46 |
| Corium, LLC | 2 | $38 |
| Edwards Lifesciences | 1 | $31 |
| Inogen, Inc. | 1 | $30 |
| Merck | 2 | $27 |
| Lilly USA, LLC | 2 | $26 |
| Sanofi Pasteur Inc. | 1 | $25 |
| GSK | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Novartis | 1 | $22 |
| Organon | 1 | $21 |
| Bardy Diagnostics, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,738 in reported general payments places this provider in the 85th percentile of 112 primary care providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 17 | $293 |
| Levothyroxine Sodium | 29 | $290 |
| Atorvastatin Calcium | 24 | $202 |
| Gabapentin | 15 | $143 |
| Amlodipine Besylate | 17 | $95 |
| Lisinopril | 15 | $72 |
| Losartan Potassium | 14 | $68 |
| Sertraline Hcl | 14 | $63 |
| Tramadol Hcl | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Other primary care in Denver
- Kaitlin KrausDenver$16K
- Mary CarrascoDenver$2K
- Loraine van SlykeDenver$1K
- Teresa SalazarDenver$1K
- Katelyn RodgersDenver$1K
- Melanie SpottsDenver$857
- Laura VillasenorDenver$802
- Lisa LumleyDenver$593
- Danielle HamstraDenver$359
- Belinda HigaDenver$299
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.